Financial toxicity and cancer treatments: Help from biosimilars – The explanatory case of bevacizumab

Subjects

Subjects :

Oncology
Cancer Research
medicine.medical_specialty
Bevacizumab
business.industry
Cancer
Biosimilar
medicine.disease
Internal medicine
Toxicity
medicine
business
medicine.drug

Details

ISSN :

09598049

Volume :

143

Database :

OpenAIRE

Journal :

European Journal of Cancer

Accession number :

edsair.doi...........20beedb64fc0750b9358fac12052ef1f

Full Text :

https://doi.org/10.1016/j.ejca.2020.11.004